Resources from the same session
243MO - Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial
Presenter: Henry M. Kuerer
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
244MO - A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (“CLEVER”)
Presenter: Angela DeMichele
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast